Andrew Hollman Meyer, Chief Business Officer at Janux Therapeutics, Inc. (JANX), sold 5,752 shares at $42.08 ($243K) on 2025-02-03, disclosed to the SEC on 2025-02-05.
Scheduled sale ($243k) by Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.08 | 2,418 | $102K | 41.9% |
| 2 | $42.08 | 2,418 | $102K | 41.9% |
| 3 | $42.77 | 816 | $35K | 14.4% |
| 4 | $43.60 | 100 | $4K | 1.8% |
| Total | $42.20 avg | 5,752 | $243K | 100% |
| Filing → |
| JANX | SELL | 2025-11-14 | $100K | — | Filing → |
| JANX | SELL | 2025-10-30 | $1.0M | — | Filing → |
| JANX | SELL | 2025-05-02 | $200K | — | Filing → |